SG11201509910YA - Phosphatidylinositol 3-kinase inhibitors - Google Patents
Phosphatidylinositol 3-kinase inhibitorsInfo
- Publication number
- SG11201509910YA SG11201509910YA SG11201509910YA SG11201509910YA SG11201509910YA SG 11201509910Y A SG11201509910Y A SG 11201509910YA SG 11201509910Y A SG11201509910Y A SG 11201509910YA SG 11201509910Y A SG11201509910Y A SG 11201509910YA SG 11201509910Y A SG11201509910Y A SG 11201509910YA
- Authority
- SG
- Singapore
- Prior art keywords
- phosphatidylinositol
- kinase inhibitors
- kinase
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361835333P | 2013-06-14 | 2013-06-14 | |
| PCT/US2014/042392 WO2014201409A1 (en) | 2013-06-14 | 2014-06-13 | Phosphatidylinositol 3-kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201509910YA true SG11201509910YA (en) | 2016-01-28 |
Family
ID=51177160
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201509910YA SG11201509910YA (en) | 2013-06-14 | 2014-06-13 | Phosphatidylinositol 3-kinase inhibitors |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US9221795B2 (en) |
| EP (1) | EP3008053B1 (en) |
| JP (1) | JP6030783B2 (en) |
| KR (1) | KR101709436B1 (en) |
| CN (1) | CN105308034B (en) |
| AR (1) | AR096621A1 (en) |
| AU (2) | AU2014277950B2 (en) |
| BR (1) | BR112015031475A2 (en) |
| CA (1) | CA2915129C (en) |
| EA (1) | EA028319B1 (en) |
| ES (1) | ES2667173T3 (en) |
| HK (2) | HK1220968A1 (en) |
| IL (1) | IL242677B (en) |
| MX (1) | MX347988B (en) |
| NO (1) | NO2994608T3 (en) |
| NZ (1) | NZ714710A (en) |
| PL (1) | PL3008053T3 (en) |
| PT (1) | PT3008053T (en) |
| SG (1) | SG11201509910YA (en) |
| SI (1) | SI3008053T1 (en) |
| TR (1) | TR201806822T4 (en) |
| TW (1) | TWI644909B (en) |
| UY (1) | UY35617A (en) |
| WO (1) | WO2014201409A1 (en) |
Families Citing this family (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG187425A1 (en) | 2008-01-04 | 2013-02-28 | Intellikine Llc | Certain chemical entities, compositions and methods |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| CN103002738A (en) | 2010-05-21 | 2013-03-27 | 英特利凯恩有限责任公司 | Chemical compounds, compositions and methods for kinase modulation |
| PE20141303A1 (en) | 2011-01-10 | 2014-10-01 | Infinity Pharmaceuticals Inc | PROCEDURE FOR PREPARING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES |
| US8785470B2 (en) | 2011-08-29 | 2014-07-22 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
| CA2915129C (en) * | 2013-06-14 | 2021-07-27 | Gilead Sciences, Inc. | Phosphatidylinositol 3-kinase inhibitors |
| EP3046563B1 (en) | 2013-09-22 | 2019-05-29 | Calitor Sciences, LLC | Substituted aminopyrimidine compounds as pi3-kinase inhibitors |
| WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| US10092563B2 (en) | 2014-06-13 | 2018-10-09 | Gilead Sciences, Inc. | Phosphatidylinositol 3-kinase inhibitors |
| MX2016016528A (en) | 2014-06-13 | 2017-03-27 | Gilead Sciences Inc | Phosphatidylinositol 3-kinase inhibitors. |
| WO2015191726A1 (en) | 2014-06-13 | 2015-12-17 | Gilead Sciences, Inc. | Phosphatidylinositol 3-kinase inhibitors |
| KR20170015508A (en) | 2014-06-13 | 2017-02-08 | 길리애드 사이언시즈, 인코포레이티드 | Quinazolinone derivatives as phosphatidylinositol 3-kinase inhibitors |
| WO2016001855A1 (en) | 2014-07-04 | 2016-01-07 | Lupin Limited | Quinolizinone derivatives as pi3k inhibitors |
| US9637488B2 (en) | 2015-01-29 | 2017-05-02 | Fuqiang Ruan | Heterocyclic compounds as inhibitors of class I PI3KS |
| TW201639573A (en) | 2015-02-03 | 2016-11-16 | 吉李德科學股份有限公司 | Combination therapies for treating cancers |
| GB201506786D0 (en) * | 2015-04-21 | 2015-06-03 | Ucb Biopharma Sprl | Therapeutic use |
| US9957267B2 (en) | 2015-07-01 | 2018-05-01 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
| TW201725044A (en) | 2015-10-01 | 2017-07-16 | 基利科學股份有限公司 | Combination of a BTK inhibitor and a checkpoint inhibitor for treating cancers |
| BR112017002594A2 (en) | 2015-12-17 | 2017-12-19 | Gilead Sciences Inc | tank binding kinase inhibitor compounds |
| JP2019510752A (en) | 2016-03-04 | 2019-04-18 | ギリアード サイエンシーズ， インコーポレイテッド | Compositions and combinations of autotaxin inhibitors |
| CA3124815A1 (en) | 2016-03-05 | 2017-09-14 | Hangzhou Zhengxiang Pharmaceuticals Co., Ltd. | Quinoline analogs as phosphatidylinositol 3-kinase inhibitors |
| US20170306050A1 (en) | 2016-04-08 | 2017-10-26 | Gilead Sciences, Inc. | Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases |
| UA126905C2 (en) | 2016-06-13 | 2023-02-22 | Ай-Маб Байофарма Юес Лімітед | Anti-pd-l1 antibodies and uses thereof |
| MX2018016227A (en) | 2016-06-24 | 2019-07-08 | Infinity Pharmaceuticals Inc | Combination therapies. |
| CA3032813A1 (en) | 2016-08-04 | 2018-02-08 | Gilead Sciences, Inc. | Cobicistat for use in cancer treatments |
| TW201815787A (en) * | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | Phosphatidylinositol 3-kinase inhibitors |
| TW201825465A (en) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | Phosphatidylinositol 3-kinase inhibitors |
| TW201813963A (en) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | Phosphatidylinositol 3-kinase inhibitors |
| CN108017641B (en) * | 2016-11-02 | 2021-01-05 | 深圳铂立健医药有限公司 | Pyrazolopyrimidine compound as PI3K inhibitor and application thereof |
| US20180133212A1 (en) | 2016-11-03 | 2018-05-17 | Gilead Sciences, Inc. | Combination of a bcl-2 inhibitor and a bromodomain inhibitor for treating cancer |
| US20180141939A1 (en) | 2016-11-22 | 2018-05-24 | Gilead Sciences, Inc. | Solid forms of a bet inhibitor |
| EP4050030A1 (en) | 2017-01-24 | 2022-08-31 | I-Mab Biopharma US Limited | Anti-cd73 antibodies and uses thereof |
| CA3054403A1 (en) | 2017-02-24 | 2018-08-30 | Gilead Sciences, Inc. | Inhibitors of bruton's tyrosine kinase |
| WO2018156901A1 (en) | 2017-02-24 | 2018-08-30 | Gilead Sciences, Inc. | Inhibitors of bruton's tyrosine kinase |
| JOP20180040A1 (en) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | Pd-1/pd-l1 inhibitors |
| WO2019023278A1 (en) | 2017-07-25 | 2019-01-31 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
| CN111566120B (en) | 2017-12-20 | 2023-09-29 | 捷克共和国有机化学与生物化学研究所 | 3' cyclic dinucleotides with phosphonate bonds of activated STING adaptor protein |
| WO2019123339A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| US10751339B2 (en) | 2018-01-20 | 2020-08-25 | Sunshine Lake Pharma Co., Ltd. | Substituted aminopyrimidine compounds and methods of use |
| TWI707849B (en) | 2018-02-13 | 2020-10-21 | 美商基利科學股份有限公司 | Pd-1/pd-l1 inhibitors |
| TW202005654A (en) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | 2'2'-cyclic dinucleotides |
| JP7296398B2 (en) | 2018-04-06 | 2023-06-22 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． | 3'3'-cyclic dinucleotide |
| TWI818007B (en) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-cyclic dinucleotides |
| US10442799B1 (en) | 2018-04-07 | 2019-10-15 | Fuqiang Ruan | Heterocyclic compounds and uses thereof |
| TWI712412B (en) | 2018-04-19 | 2020-12-11 | 美商基利科學股份有限公司 | Pd-1/pd-l1 inhibitors |
| TW202014193A (en) | 2018-05-03 | 2020-04-16 | 捷克科學院有機化學與生物化學研究所 | 2’3’-cyclic dinucleotides comprising carbocyclic nucleotide |
| CA3098873A1 (en) | 2018-05-11 | 2019-11-14 | Phosphorex, Inc. | Microparticles and nanoparticles having negative surface charges |
| WO2019222112A1 (en) | 2018-05-14 | 2019-11-21 | Gilead Sciences, Inc. | Mcl-1 inhibitors |
| WO2020014643A1 (en) | 2018-07-13 | 2020-01-16 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| US11179397B2 (en) | 2018-10-03 | 2021-11-23 | Gilead Sciences, Inc. | Imidazopyrimidine derivatives |
| CN112955435A (en) | 2018-10-24 | 2021-06-11 | 吉利德科学公司 | PD-1/PD-L1 inhibitors |
| MX2021005047A (en) | 2018-10-31 | 2021-09-08 | Gilead Sciences Inc | Substituted 6-azabenzimidazole compounds as hpk1 inhibitors. |
| WO2020092528A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
| US20220143061A1 (en) | 2019-03-07 | 2022-05-12 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| DK3934757T3 (en) | 2019-03-07 | 2023-04-17 | Inst Of Organic Chemistry And Biochemistry Ascr V V I | 2'3'-CYCLIC DINUCLEOTIDES AND THEIR PRODUCTS |
| EP3935065A1 (en) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| TW202212339A (en) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | Solid forms of a toll-like receptor modulator |
| TW202210480A (en) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | Solid forms of a toll-like receptor modulator |
| TWI826690B (en) | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | Substituted eneoxindoles and uses thereof |
| BR112021026376A2 (en) | 2019-06-25 | 2022-05-10 | Gilead Sciences Inc | flt3l-fc fusion proteins and methods of use |
| CA3145791A1 (en) | 2019-07-16 | 2021-01-21 | Gilead Sciences, Inc. | Hiv vaccines and methods of making and using |
| PE20221111A1 (en) | 2019-09-30 | 2022-07-11 | Gilead Sciences Inc | HBV VACCINES AND HBV TREATMENT METHODS |
| KR20220085796A (en) | 2019-10-18 | 2022-06-22 | 포티 세븐, 인코포레이티드 | Combination Therapy to Treat Myelodysplastic Syndrome and Acute Myelogenous Leukemia |
| KR20220091576A (en) | 2019-10-31 | 2022-06-30 | 포티 세븐, 인코포레이티드 | Anti-CD47 and Anti-CD20 Based Treatment of Hematological Cancers |
| TWI778443B (en) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1 inhibitors |
| KR20220131918A (en) | 2019-12-24 | 2022-09-29 | 카나 바이오사이언스, 인코포레이션 | Diacylglycerol Kinase Modulating Compounds |
| BR112022014623A2 (en) | 2020-02-14 | 2022-09-13 | Jounce Therapeutics Inc | ANTIBODIES AND FUSION PROTEINS THAT BIND CCR8 AND USES THEREOF |
| US20230039553A1 (en) | 2020-05-01 | 2023-02-09 | Gilead Sciences, Inc. | Cd73 compounds |
| TW202302145A (en) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | Co-inhibition of cd47/sirpα binding and nedd8-activating enzyme e1 regulatory subunit for the treatment of cancer |
| US20220389394A1 (en) | 2021-05-18 | 2022-12-08 | Gilead Sciences, Inc. | METHODS OF USING FLT3L-Fc FUSION PROTEINS |
| CA3220923A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| US20230046340A1 (en) | 2021-06-23 | 2023-02-16 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CA3222595A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| TW202330504A (en) | 2021-10-28 | 2023-08-01 | 美商基利科學股份有限公司 | Pyridizin-3(2h)-one derivatives |
| US11919869B2 (en) | 2021-10-29 | 2024-03-05 | Gilead Sciences, Inc. | CD73 compounds |
| WO2023107956A1 (en) | 2021-12-08 | 2023-06-15 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and 5t4 |
| US20230220106A1 (en) | 2021-12-08 | 2023-07-13 | Dragonfly Therapeutics, Inc. | Antibodies targeting 5t4 and uses thereof |
| US20230242508A1 (en) | 2021-12-22 | 2023-08-03 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| US20240124412A1 (en) | 2021-12-22 | 2024-04-18 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202340168A (en) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Parp7 inhibitors |
| US20230373950A1 (en) | 2022-03-17 | 2023-11-23 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| US20230355796A1 (en) | 2022-03-24 | 2023-11-09 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| TW202345901A (en) | 2022-04-05 | 2023-12-01 | 美商基利科學股份有限公司 | Combination therapy for treating colorectal cancer |
| TW202400138A (en) | 2022-04-21 | 2024-01-01 | 美商基利科學股份有限公司 | Kras g12d modulating compounds |
| US20240116928A1 (en) | 2022-07-01 | 2024-04-11 | Gilead Sciences, Inc. | Cd73 compounds |
| WO2024015741A1 (en) | 2022-07-12 | 2024-01-18 | Gilead Sciences, Inc. | Hiv immunogenic polypeptides and vaccines and uses thereof |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4965288A (en) | 1988-02-25 | 1990-10-23 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US5182297A (en) | 1988-02-25 | 1993-01-26 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US5252608A (en) | 1988-02-25 | 1993-10-12 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US4943593A (en) | 1988-02-25 | 1990-07-24 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US5021456A (en) | 1988-02-25 | 1991-06-04 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US5059714A (en) | 1988-02-25 | 1991-10-22 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| US5120764A (en) | 1988-11-01 | 1992-06-09 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US4997854A (en) | 1989-08-25 | 1991-03-05 | Trustees Of Boston University | Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in-situ using adjacently positioned diamine analogue substrates |
| GB9611460D0 (en) | 1996-06-01 | 1996-08-07 | Ludwig Inst Cancer Res | Novel lipid kinase |
| US5858753A (en) | 1996-11-25 | 1999-01-12 | Icos Corporation | Lipid kinase |
| ES2245015T3 (en) | 1997-06-09 | 2005-12-16 | Pfizer Products Inc. | QUINAZOLIN-4-ONAS AS AMPA ANTAGONISTS. |
| AU780846B2 (en) | 1999-09-16 | 2005-04-21 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| KR20050049562A (en) | 1999-10-27 | 2005-05-25 | 싸이토키네틱스, 인코포레이티드 | Methods and compositions utilizing quinazolinones |
| US6545004B1 (en) | 1999-10-27 | 2003-04-08 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
| AU5566701A (en) | 2000-04-25 | 2001-11-07 | Icos Corp | Inhibitors of human phosphatidyl-inositol 3-kinase delta |
| US6667300B2 (en) * | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
| FR2828206B1 (en) | 2001-08-03 | 2004-09-24 | Centre Nat Rech Scient | USE OF LYSYL OXIDASE INHIBITORS FOR CELL CULTURE AND TISSUE ENGINEERING |
| EP1521746B1 (en) | 2002-03-07 | 2011-04-27 | X-Ceptor Therapeutics, Inc. | Quinazolinone modulators of nuclear receptors |
| US20040132732A1 (en) | 2002-10-21 | 2004-07-08 | Wei Han | Quinazolinones and derivatives thereof as factor Xa inhibitors |
| ATE538103T1 (en) | 2003-11-25 | 2012-01-15 | Novartis Ag | QUINAZOLINONE COMPOUNDS AS ANTICANCER AGENTS |
| EP1761540B1 (en) | 2004-05-13 | 2016-09-28 | Icos Corporation | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
| BRPI0512075A (en) | 2004-06-15 | 2008-02-06 | Astrazeneca Ab | compound, process for the preparation thereof, pharmaceutical composition, use of a compound, and methods for producing a b-raf inhibiting effect, and an anticancer effect on a warm-blooded animal, and for treating a disease |
| US7939538B2 (en) | 2004-06-28 | 2011-05-10 | Amgen Inc. | Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases |
| DE102005024017A1 (en) | 2005-05-25 | 2006-11-30 | Merck Patent Gmbh | quinazolinones |
| EP2139882B1 (en) | 2007-03-23 | 2013-12-25 | Amgen Inc. | 3- substituted quinoline or quinoxaline derivatives and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors |
| US20110217300A1 (en) | 2007-06-22 | 2011-09-08 | Arqule, Inc. | Quinazolinone Compounds and Methods of Use Thereof |
| SG187425A1 (en) | 2008-01-04 | 2013-02-28 | Intellikine Llc | Certain chemical entities, compositions and methods |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| WO2010036380A1 (en) | 2008-09-26 | 2010-04-01 | Intellikine, Inc. | Heterocyclic kinase inhibitors |
| WO2010059593A1 (en) | 2008-11-18 | 2010-05-27 | Intellikine, Inc. | Methods and compositions for treatment of ophthalmic conditions |
| WO2010092340A1 (en) | 2009-02-13 | 2010-08-19 | Ucb Pharma S.A. | Fused pyridine and pyrazine derivatives as kinase inhibitors |
| JP5789252B2 (en) | 2009-05-07 | 2015-10-07 | インテリカイン， エルエルシー | Heterocyclic compounds and uses thereof |
| US20100331306A1 (en) | 2009-06-25 | 2010-12-30 | Amgen Inc. | Heterocyclic compounds and their uses |
| WO2010151735A2 (en) | 2009-06-25 | 2010-12-29 | Amgen Inc. | Heterocyclic compounds and their uses |
| TWI499592B (en) | 2009-09-09 | 2015-09-11 | Avila Therapeutics Inc | Pi3 kinase inhibitors and uses thereof |
| WO2011058113A1 (en) | 2009-11-12 | 2011-05-19 | Ucb Pharma S.A. | Fused bicyclic pyridine and pyrazine derivatives as kinase inhibitors |
| WO2011075628A1 (en) | 2009-12-18 | 2011-06-23 | Amgen Inc. | Heterocyclic compounds and their uses |
| CA2784830C (en) | 2009-12-18 | 2018-03-27 | Sunovion Pharmaceuticals Inc. | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
| UY33304A (en) | 2010-04-02 | 2011-10-31 | Amgen Inc | HETEROCYCLIC COMPOUNDS AND THEIR USES |
| CN103002738A (en) * | 2010-05-21 | 2013-03-27 | 英特利凯恩有限责任公司 | Chemical compounds, compositions and methods for kinase modulation |
| EP3318561B1 (en) | 2010-05-26 | 2021-12-22 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
| JP2013530238A (en) | 2010-07-01 | 2013-07-25 | アムジエン・インコーポレーテツド | Heterocyclic compounds and their use as inhibitors of PI3K activity |
| CA2803624A1 (en) | 2010-07-02 | 2012-01-05 | Jason A. Duquette | Heterocyclic compounds and their use as inhibitors of pi3k activity |
| AR082985A1 (en) * | 2010-09-14 | 2013-01-23 | Exelixis Inc | PI3K-d INHIBITORS AND METHODS OF USE AND PREPARATION |
| US8765773B2 (en) | 2010-10-18 | 2014-07-01 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
| JP2013541591A (en) | 2010-11-04 | 2013-11-14 | アムジエン・インコーポレーテツド | Heterocyclic compounds and their use |
| US8901133B2 (en) | 2010-11-10 | 2014-12-02 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| EP2640715A1 (en) | 2010-11-17 | 2013-09-25 | Amgen Inc. | Quinoline derivatives as pik3 inhibitors |
| EP2655342A1 (en) | 2010-12-23 | 2013-10-30 | Amgen Inc. | Heterocyclic compounds and their uses |
| PE20141303A1 (en) | 2011-01-10 | 2014-10-01 | Infinity Pharmaceuticals Inc | PROCEDURE FOR PREPARING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES |
| CA2825028A1 (en) | 2011-02-09 | 2012-08-16 | F. Hoffman-La Roche Ag | Heterocyclic compounds as pi3 kinase inhibitors |
| US9108984B2 (en) | 2011-03-14 | 2015-08-18 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors |
| US9126948B2 (en) | 2011-03-25 | 2015-09-08 | Incyte Holdings Corporation | Pyrimidine-4,6-diamine derivatives as PI3K inhibitors |
| EP2518071A1 (en) | 2011-04-29 | 2012-10-31 | Almirall, S.A. | Imidazopyridine derivatives as PI3K inhibitors |
| EP2518070A1 (en) | 2011-04-29 | 2012-10-31 | Almirall, S.A. | Pyrrolotriazinone derivatives as PI3K inhibitors |
| US8785470B2 (en) | 2011-08-29 | 2014-07-22 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US9202145B2 (en) | 2012-11-30 | 2015-12-01 | Safety Management Services, Inc. | System and method of determining material reaction or sensitivity using high-speed video frames |
| EP2941426B1 (en) * | 2012-12-21 | 2018-06-13 | Gilead Calistoga LLC | Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors |
| PT2935246T (en) | 2012-12-21 | 2018-10-10 | Gilead Calistoga Llc | Isoquinolinone or quinazolinone phosphatidylinositol 3-kinase inhibitors |
| CA2915129C (en) * | 2013-06-14 | 2021-07-27 | Gilead Sciences, Inc. | Phosphatidylinositol 3-kinase inhibitors |
-
2014
- 2014-06-13 CA CA2915129A patent/CA2915129C/en active Active
- 2014-06-13 TW TW103120507A patent/TWI644909B/en active
- 2014-06-13 SI SI201430672T patent/SI3008053T1/en unknown
- 2014-06-13 PL PL14738957T patent/PL3008053T3/en unknown
- 2014-06-13 WO PCT/US2014/042392 patent/WO2014201409A1/en active Application Filing
- 2014-06-13 BR BR112015031475A patent/BR112015031475A2/en not_active IP Right Cessation
- 2014-06-13 TR TR2018/06822T patent/TR201806822T4/en unknown
- 2014-06-13 SG SG11201509910YA patent/SG11201509910YA/en unknown
- 2014-06-13 CN CN201480033119.7A patent/CN105308034B/en active Active
- 2014-06-13 ES ES14738957.1T patent/ES2667173T3/en active Active
- 2014-06-13 JP JP2015563142A patent/JP6030783B2/en active Active
- 2014-06-13 MX MX2015017192A patent/MX347988B/en active IP Right Grant
- 2014-06-13 AR ARP140102277A patent/AR096621A1/en unknown
- 2014-06-13 EA EA201592182A patent/EA028319B1/en not_active IP Right Cessation
- 2014-06-13 US US14/304,539 patent/US9221795B2/en active Active
- 2014-06-13 NZ NZ714710A patent/NZ714710A/en not_active IP Right Cessation
- 2014-06-13 AU AU2014277950A patent/AU2014277950B2/en active Active
- 2014-06-13 EP EP14738957.1A patent/EP3008053B1/en active Active
- 2014-06-13 PT PT147389571T patent/PT3008053T/en unknown
- 2014-06-13 KR KR1020157035901A patent/KR101709436B1/en active IP Right Grant
- 2014-06-16 UY UY0001035617A patent/UY35617A/en not_active Application Discontinuation
- 2014-07-31 NO NO14832802A patent/NO2994608T3/no unknown
-
2015
- 2015-10-21 US US14/919,261 patent/US20160039793A1/en not_active Abandoned
- 2015-11-19 IL IL242677A patent/IL242677B/en not_active IP Right Cessation
-
2016
- 2016-03-11 AU AU2016201584A patent/AU2016201584B2/en not_active Ceased
- 2016-07-27 HK HK16108969.2A patent/HK1220968A1/en unknown
- 2016-09-09 HK HK16110710.0A patent/HK1223911A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1223911A1 (en) | Phosphatidylinositol 3-kinase inhibitors 3- | |
| HK1231474A1 (en) | Phosphatidylinositol 3-kinase inhibitors 3- | |
| HK1231477A1 (en) | Phosphatidylinositol 3-kinase inhibitors 3- | |
| HK1231476A1 (en) | Phosphatidylinositol 3-kinase inhibitors 3- | |
| HK1220459A1 (en) | Kinase inhibitors | |
| EP2970340A4 (en) | Beta-lactamase inhibitors | |
| EP2943204A4 (en) | Beta-lactamase inhibitors | |
| IL249079A0 (en) | Phosphatidylinositol 3-kinase inhibitors | |
| HK1211578A1 (en) | Amidoimidazopyridazines as mknk-1 kinase inhibitors mknk-1 | |
| SG11201609540TA (en) | Phosphatidylinositol 3-kinase inhibitors | |
| HK1219104A1 (en) | Kinase inhibitors | |
| HK1216531A1 (en) | Novel inhibitors | |
| HK1224281A1 (en) | Process methods for phosphatidylinositol 3-kinase inhibitors 3- | |
| IL245442A0 (en) | Gsk-3 inhibitors | |
| IL242803A0 (en) | Dihydropyridinone mgat2 inhibitors | |
| GB201314578D0 (en) | Bicyclic inhibitors | |
| HK1222339A1 (en) | Inhibitors of metallo-ss-lactamase-enzymes -- | |
| AP2015008843A0 (en) | Imidazo-triazine derivatives as pde10 inhibitors | |
| EP2968324A4 (en) | Substituted pyridizinone derivatives as pde10 inhibitors | |
| GB201307155D0 (en) | Kinase inhibitors | |
| GB201320835D0 (en) | HIF inhibitors | |
| GB201323021D0 (en) | Use of kinase inhibitors | |
| GB201321227D0 (en) | Use of kinase inhibitors | |
| GB201309603D0 (en) | Novel compounds and their use as kinase inhibitors | |
| GB201305741D0 (en) | Novel compounds and their use as kinase inhibitors |